David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.
Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Beverly Hills, CA, USA.
Sex Med Rev. 2019 Apr;7(2):223-250. doi: 10.1016/j.sxmr.2017.12.004. Epub 2018 Feb 3.
Female sexual dysfunction (FSD) is a highly prevalent condition. Nevertheless, the scientific literature has only recently begun to accumulate evidence for treatment modalities that address the underlying etiologies of FSD.
The purpose of this systematic review is to elucidate what treatments are effective across the various symptom complexes of FSD.
Utilizing Meta-analysis of Observational Studies in Epidemiology guidelines, we conducted a systematic review of PubMed, EMBASE, clinicaltrials.gov, and the Cochrane Review databases. Eleven search strings, encompassing the terms "female sexual dysfunction" and "treatment," in combination with "vulvovaginal atrophy," "vaginismus," "vaginal atrophy," "vulvodynia," "vestibulitis," "hypoactive sexual desire," "arousal disorder," "sexual pain disorder," "genitourinary syndrome of menopause," and "orgasmic disorder" were utilized. 605 Relevant articles were retrieved. A total of 103 original studies met inclusion criteria.
We assess peer-reviewed literature.
42 Treatment modalities were utilized, including 26 different classes of medications. Although outcome measures varied, the most substantial improvement across multiple studies was noted with various hormonal regimens. The most common treatments included hormonal therapy (25 studies), phosphodiesterase type-5 inhibitors (9 studies), botulinum toxin A (5 studies), and flibanserin (5 studies). The psychotherapeutic approach was detailed in 36 articles while 3 studies utilized homeopathic treatments. Numerous treatments showed efficacy in a single case series, including the promising results associated with the micro-ablative carbon-dioxide laser. Despite the marked improvement in specific FSD domains, neither pharmacologic treatments nor psychotherapeutic interventions demonstrate consistent disease resolution.
Treatment of FSD is multi-factorial; medications alone do not resolve FSD. The wide variability of treatment and outcome measures across the literature attests to the complexity of FSD and the need for a treatment algorithm that addresses all 4 domains of FSD. Weinberger JM, Houman J, Caron AT, et al. Female Sexual Dysfunction: A Systematic Review of Outcomes Across Various Treatment Modalities. Sex Med Rev 2019;7:223-250.
女性性功能障碍(FSD)是一种高发疾病。然而,科学文献才刚刚开始积累针对 FSD 潜在病因的治疗方法的证据。
本系统评价旨在阐明针对 FSD 各种症状综合的有效治疗方法。
我们根据观察性研究的荟萃分析指南,对 PubMed、EMBASE、clinicaltrials.gov 和 Cochrane 评价数据库进行了系统评价。我们使用了 11 个搜索字符串,其中包括“女性性功能障碍”和“治疗”这两个术语,以及“外阴阴道萎缩”、“阴道痉挛”、“阴道萎缩”、“外阴痛”、“外阴前庭炎”、“性欲低下”、“唤起障碍”、“性疼痛障碍”、“女性生殖泌尿系统绝经后综合征”和“性高潮障碍”。共检索到 605 篇相关文章,其中共有 103 项原始研究符合纳入标准。
我们评估了同行评议文献。
FSD 的治疗方法是多因素的;单独使用药物并不能解决 FSD 问题。文献中治疗和结果测量的广泛差异证明了 FSD 的复杂性,需要制定一种治疗算法来解决 FSD 的所有 4 个领域。Weinberger JM, Houman J, Caron AT, et al. Female Sexual Dysfunction: A Systematic Review of Outcomes Across Various Treatment Modalities. Sex Med Rev 2019;7:223-250.